Invasive fungal infections: a review of epidemiology and management options.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Medical Microbiology

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1099/JMM.0.46548-0PMID 16772406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

  2005cited by this paper
• Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease.

  2005cited by this paper
• Posaconazole: a broad-spectrum triazole antifungal.

  2005cited by this paper
• International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

  2005cited by this paper
• Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials

  2005cited by this paper
• Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

  2005cited by this paper
• Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study

  2004cited by this paper
• Guidelines for treatment of candidiasis.

  2004cited by this paper
• Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.

  2004cited by this paper
• Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

  2004influential reference
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• Candidosis in the intensive care unit: a 20-year survey.

  2004cited by this paper
• Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

  2004cited by this paper
• Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

  2004cited by this paper
• Echinocandin antifungal drugs.

  2003cited by this paper
• Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi

  2003influential reference
• Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients.

  2003cited by this paper
• Epidemiology of Aspergillus terreus at a University Hospital

  2003cited by this paper
• A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

  2003cited by this paper
• Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

  2003influential reference
• Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.

  2003cited by this paper
• Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.

  2003cited by this paper
• A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

  2003cited by this paper
• Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.

  2003cited by this paper
• Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.

  2003cited by this paper
• Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

  2003cited by this paper
• Voriconazole: A New Triazole Antifungal Agent

  2003cited by this paper
• Management and outcome of bloodstream infections due to Candida species in England and Wales.

  2003influential reference
• Galactomannan detection in computerized tomography‐based broncho‐alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis

  2003cited by this paper
• Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

  2003influential reference
• Invasive Pulmonary Aspergillosis Soon After Therapy With Infliximab, a Tumor Necrosis Factor-Alpha–Neutralizing Antibody: A Possible Healthcare-Associated Case?

  2003cited by this paper
• Fungal Infections in Solid Organ Transplant Patients

  2003influential reference
• In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood

  2003cited by this paper
• Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

  2003cited by this paper
• In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.

  2002cited by this paper
• In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes

  2002influential reference
• Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

  2002cited by this paper
• Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

  2002influential reference
• European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region.

  2002cited by this paper
• A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.

  2002cited by this paper
• Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

  2002cited by this paper
• Treatment of Scedosporium apiospermum brain abscesses with posaconazole.

  2002cited by this paper
• NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM H. SECULAR TREND OF HOSPITAL-ACQUIRED CANDIDEMIA AMONG INTENSIVE CARE UNIT PATIENTS IN THE UNITED STATES DURING 1989-1999

  2002cited by this paper
• Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans.

  2002cited by this paper
• Comparison of caspofungin and amphotericin B for invasive candidiasis.

  2002influential reference
• and the National Nosocomial Infections Surveillance System Hospitals

  2002cited by this paper
• 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer

  2002cited by this paper
• A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.

  2001cited by this paper
• Intravenous Itraconazole

  2001cited by this paper
• Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

  2001cited by this paper
• Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia.

  2001cited by this paper
• In Vitro Activities of Four Novel Triazoles againstScedosporium spp

  2001cited by this paper
• Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature.

  2001cited by this paper
• A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.

  2001cited by this paper
• Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy

  2001cited by this paper
• Zygomycetes in human disease.

  2000cited by this paper
• A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.

  2000cited by this paper
• Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

  2000cited by this paper
• A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia

  2000influential reference
• Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

  2000cited by this paper
• Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.

  2000influential reference
• Practice Guidelines for Diseases Caused by Aspergillus

  2000influential reference
• Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial.

  2000cited by this paper
• Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial.

  1999cited by this paper
• A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

  1999cited by this paper
• Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

  1999cited by this paper
• Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.

  1999cited by this paper
• Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

  1999influential reference
• Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.

  1999cited by this paper
• A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies

  1999influential reference
• Prophylactic Fluconazole in Liver Transplant Recipients

  1999cited by this paper
• A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.

  1999cited by this paper
• In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

  1998influential reference
• The role of immunoreconstitution in the management of refractory opportunistic fungal infections.

  1998cited by this paper
• Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.

  1998cited by this paper
• Invasive aspergillosis.

  1998cited by this paper
• Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers

  1998cited by this paper
• The epidemiology and prevention of invasive aspergillosis.

  1998cited by this paper
• An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group.

  1998cited by this paper
• Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections

  1998cited by this paper
• Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients

  1997cited by this paper
• Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.

  1997cited by this paper
• Nosocomial cerebral aspergillosis: a report of 3 cases.

  1996cited by this paper
• Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

  1995cited by this paper
• A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

  1994cited by this paper
• A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

  1994cited by this paper
• Management of deep Candida infection in surgical and intensive care unit patients. British Society for Antimicrobial Chemotherapy Working Party.

  1994cited by this paper
• Management of deepCandida infection in surgical and intensive care unit patients

  1994cited by this paper
• Invasive aspergillosis in patients with AIDS.

  1994cited by this paper
• A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

  1992cited by this paper
• A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis.

  1979influential reference
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Microbiology Standards of Care British Society for Medical Mycology Proposed Standards of Care for Patients with Invasive Fungal Infections

  year unknowncited by this paper

• Transport Protein Interaction and Target Pathway Analysis of a Hybrid Antifungal Compound synthesized by linking triazolothiadiazine ring system with the pyridine ring.

  2025cites this paper
• Antimicrobial peptide hydrogels: synthesis, ROS regulation mechanism, and multimodal therapeutic applications in drug delivery systems.

  2025cites this paper
• A novel arylnaphthalene lignan analogue targets CYP51 to inhibit Cryptococcus neoformans growth.

  2025cites this paper
• CT Findings for Differentiating Pulmonary Mucormycosis From Invasive Pulmonary Aspergillosis, Prior to Invasive Procedure Such as a Biopsy or Surgery: A 22‐Year Single‐Center Experience

  2025cites this paper
• Culture-positive mould infections in patients with haemato-oncological diseases

  2025cites this paper
• Ketoconazole Nanoparticles Based Film-Forming Spray-A Promising Breakthrough for Targeted Therapy

  2025cites this paper
• Role of glucuronoxylomannan and steryl glucosides in protecting against cryptococcosis

  2025cites this paper
• Therapeutic Potential and Clinical Translation of Nanodrugs: A Path Forward- Case Studies from Bench to Bedside

  2025cites this paper
• Paper-based CRISPR-Cas diagnostics: A comprehensive review of advances and applications in disease detection

  2025cites this paper
• Metal nanoparticles synthesis: an overview of different synthesis methods, mode of action and their biomedical application

  2025cites this paper
• Organocatalyst as a synthetic gadget for pharmaceutically potent molecules

  2024cites this paper
• Ketoconazole: A Review of It's Therapeutic Effectiveness in Superficial and Systemic Fungal Infections

  2024cites this paper
• An improved expression and purification protocol enables the structural characterization of Mnt1, an antifungal target from Candida albicans

  2024cites this paper
• Ultrasound irradiation of hydrothermally engineered sub-20 nm PbS nanoparticles and effect of their size on Aspergillus species morphology

  2024cites this paper
• Alternative and Classical Processes for Disinfection of Water Polluted by Fungi: A Systematic Review

  2024cites this paper
• Evaluation of a customised Sensititre YeastOne plate containing isavuconazole for antifungal susceptibility testing in Singapore.

  2024cites this paper
• A novel cabazitaxel liposomes modified with ginsenoside Rk1 for cancer targeted therapy

  2024cites this paper
• Systemic Candida Infection and Pulmonary Aspergillosis in an Alpaca (Vicugna pacos): A Case Report

  2024cites this paper
• Prevalence, Causes, and Management Strategies of Fungal Diseases in Northern Regions of Bangladesh

  2024cites this paper
• Data analysis of patients with positive mould or dimorphic fungal cultures from sterile sites

  2024cites this paper
• A novel fungal-targeted drug delivery system dectin-1-targeted-PEG-amino acid polymer block enhances antifungal activity and reduces cytotoxicity of amphotericin B

  2024cites this paper
• Computational Evaluation of Tridax Procumbens Phytoconstituents in Wound Healing Process

  2024cites this paper
• Adjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 mice.

  2024cites this paper
• Biogenic Synthesis, Characterization, and Antifungal Activity Studies of Copper Oxide Nanoparticles Using Aqueous Extract of Moringa oleifera Leaves

  2023cites this paper
• Características clínicas y epidemiológicas, diagnóstico y tratamiento establecido en infección fúngica invasiva en pacientes pediátricos: serie de casos

  2023cites this paper
• Oxidative stress and disruption of the antioxidant defense system as triggers of diseases

  2023cites this paper
• Fe3O4 Nanoparticles Catalyzed Tandem Synthesis of Fluorescent 3‐(4,5‐diaryl‐1H‐imidazol‐2‐yl) quinoline‐2‐amines: Solvatochromic, DFT and Biological Studies

  2023cites this paper
• Identification and Prevalence of Aspergillus sp Isolated from Bali Dog’s Skin

  2023cites this paper
• Non-traditional approaches for control of antibiotic resistance

  2023cites this paper
• The growth inhibitory and apoptotic effects of umbelliprenin in a mouse model of systemic candidiasis.

  2023cites this paper
• Molecular Diagnostics for Invasive Fungal Infections: Barriers to Widespread Adoption and Opportunities for Improvement

  2023cites this paper
• A mathematic equation derived from host-pathogen interactions elucidates the significance of integrating modern medicine with traditional Chinese medicine to treat infectious diseases.

  2023cites this paper
• Early cryptococcosis infection in a liver transplant patient: A case report

  2023cites this paper
• Synthesis, Antifungal Ergosterol Inhibition, Antibiofilm Activities, and Molecular Docking on β-Tubulin and Sterol 14-Alpha Demethylase along with DFT-Based Quantum Mechanical Calculation of Pyrazole Containing Fused Pyridine–Pyrimidine Derivatives

  2023cites this paper
• A Comprehensive Review of Identification Methods for Pathogenic Yeasts: Challenges and Approaches

  2023influential citation
• Toxicity Study and Binding Analysis of Newly Synthesized Antifungal N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide Derivative with Bovine Serum Albumin

  2023cites this paper
• Click chemistry inspired syntheses of new amide linked 1,2,3-triazoles from naphthols: biological evaluation and in silico computational study

  2023cites this paper
• Identification of Fungal Isolates in Patients With Pulmonary Tuberculosis Treated at a Tertiary Care Hospital

  2023cites this paper
• Antifungal Compounds from the Leaves of Rhynchosia minima

  2022cites this paper
• Human Clinical Isolates of Pathogenic Fungi Are Host to Diverse Mycoviruses

  2022cites this paper
• Growth Performance and Recovery of Nosocomial Aspergillus spp. in Blood Culture Bottles

  2022cites this paper
• Fungal spore distribution in two hospitals in Kabale district, Uganda

  2022cites this paper
• Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens

  2022cites this paper
• Adjuvant Curdlan Contributes to Immunization against Cryptococcus gattii Infection in a Mouse Strain-Specific Manner

  2022cites this paper
• Synergistic Antifungal Activity of Phellodendri Cortex and Magnoliae Cortex against Candida albicans

  2022cites this paper
• Evaluation of the relevance of use of the BD-BACTEC®MycosisIC/F, BD-BACTEC®PlusAerobic/F, BD-BACTEC®Lytic/10 anaerobic/F and BD-BACTEC®PedsPlus/F culture bottle system for fungemia detection: A 4-year retrospective study at the Dijon university hospital, France.

  2022cites this paper
• Invasive and Subcutaneous Infections Caused by Filamentous Fungi: Report from a Portuguese Multicentric Surveillance Program

  2022cites this paper
• Nascent Nanoformulations as an Insight Into the Limitations of the Conventional Systemic Antifungal Therapies.

  2022cites this paper
• Antifungal Activity of NP20 Derived from Amphioxus Midkine/Pleiotrophin Homolog Against Aspergillus niger and Aspergillus fumigatus

  2022cites this paper
• Plant-Mediated Green Synthesis of Ag NPs and Their Possible Applications: A Critical Review

  2022cites this paper
• The increasing problem of treatment‐resistant fungal infections: a call for antifungal stewardship programs

  2021cites this paper
• Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole

  2021cites this paper
• Developing Two Rapid Protein Extraction Methods Using Focused-Ultrasonication and Zirconia-Silica Beads for Filamentous Fungi Identification by MALDI-TOF MS

  2021cites this paper
• The impact of lemongrass, oregano, and thyme essential oils on Candida albicans’ virulence factors

  2021cites this paper
• Computational Drug Repurposing Resources and Approaches for Discovering Novel Antifungal Drugs against Candida albicans N-Myristoyl Transferase

  2021cites this paper
• Phialemoniopsis limonesiae sp. nov. causing cutaneous phaeohyphomycosis in an immunosuppressed woman

  2021cites this paper
• In vivo active organometallic-containing antimycotic agents

  2021cites this paper
• Groups of pathogens that cause opportunistic pneumomycoses in TB patients: the protocol of laboratory studies, the activity of drugs

  2021cites this paper
• Pro ling of Pulmonary Fungal Pathogens and the Prevalence of Pulmonary Tuberculosis Fungal Co- Infection in Presumptive Tuberculosis Patients Referred to Saint Peter’s Tuberculosis Referral Hospital, Addis Ababa, Ethiopia

  2021cites this paper
• Association of Fungal Siderophores in Human Diseases: Roles and Treatments

  2021cites this paper
• Delivery strategies of amphotericin B for invasive fungal infections

  2021cites this paper
• Fungal natural products galaxy: Biochemistry and molecular genetics toward blockbuster drugs discovery.

  2021cites this paper
• Profiling of potential pulmonary fungal pathogens and the prevalence of the association between pulmonary tuberculosis and potential fungal pathogens in presumptive tuberculosis patients referred to Saint Peter’s Specialized Tuberculosis Referral Hospital, Addis Ababa, Ethiopia

  2021cites this paper
• Synthesis of fish scale derived hydroxyapatite silica propyl bis aminoethoxy ethane cuprous complex (HASPBAEECC) as a novel hybrid nano-catalyst for highly efficient synthesis of new benzimidazole-1,2,3-triazole hybrid analogues as antifungal agents

  2021cites this paper
• Symbiosis and Dysbiosis of the Human Mycobiome

  2021cites this paper
• PET imaging in invasive fungal infection

  2021cites this paper
• Does Systemic Methotrexate Therapy Induce Azole Resistance among Endogenous Candida Strains?

  2021cites this paper
• Isavuconazole: Thermodynamic Evaluation of Processes Sublimation, Dissolution and Partition in Pharmaceutically Relevant Media

  2021cites this paper
• Alleviating the toxicity concerns of antibacterial cinnamon‐polycaprolactone biomaterials for healthcare‐related biomedical applications

  2021cites this paper
• The Antimicrobial Activity of Omiganan Alone and In Combination against Candida Isolated from Vulvovaginal Candidiasis and Bloodstream Infections

  2021cites this paper
• Development and Validation of a LC-MS/MS Method for the Profiling of Impurities Formed during Stress Study of Antifungal Agent-Efinaconazole.

  2021cites this paper
• Performance Evaluation of VITEK MS for the Identification of a Wide Spectrum of Clinically Relevant Filamentous Fungi Using a Korean Collection

  2021cites this paper
• Aspergillus from Different Habitats and Their Industrial Applications

  2021cites this paper
• Identification of repositionable drugs with novel antimycotic activity by screening Prestwick Chemical Library against emerging invasive molds.

  2020cites this paper
• Secondary Metabolites and Toxins of Microbial Origin for the Treatment of Diseases

  2020cites this paper
• Candida spp. Isoladas de área natural e de cultivo: resistência a fluconazol como biomarcador ambiental / Candida spp. Natural area and cultival isolated: resistance to fluconazole as an environmental biomarker

  2020cites this paper
• Diagnostic Mycology: Xtreme Challenges

  2020cites this paper
• A multicenter prospective study evaluating the impact of Proton Pump Inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.

  2020cites this paper
• Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.

  2020cites this paper
• A review on synthetic procedures and applications of phosphorus oxychloride (POCl3) in the last biennial period (2018–19)

  2020cites this paper
• Selective antifungal activity of silver nanoparticles: A comparative study between Candida tropicalis and Saccharomyces boulardii

  2020cites this paper
• A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates

  2020cites this paper
• Evaluation of Antimicrobial Activity of Trachyspermum ammi (L.) Sprague Essential Oil and Its Active Constituent, Thymol, against Vaginal Pathogens

  2020cites this paper
• Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis

  2020cites this paper
• Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.

  2020cites this paper
• Pharmacokinetic and Pharmacodynamic Comparison of Intravenous and Inhaled Caspofungin

  2020cites this paper
• Antifungal Activity of Gepinacin Scaffold Glycosylphosphatidylinositol Anchor Biosynthesis Inhibitors with Improved Metabolic Stability

  2020cites this paper
• Antifungal Therapy in Fungal Necrotizing Soft Tissue Infections.

  2020cites this paper
• Interactions of FK506 and Rapamycin With FK506 Binding Protein 12 in Opportunistic Human Fungal Pathogens

  2020influential citation
• New N‐phenylacetamide‐linked 1,2,3‐triazole‐tethered coumarin conjugates: Synthesis, bioevaluation, and molecular docking study

  2020cites this paper
• Environmental Factors and Ventilation Affect Concentrations of Microorganisms in Hospital Wards of Southern Thailand

  2020cites this paper
• Recent Advances in Therapeutic Applications of Bisbenzimidazoles.

  2020cites this paper
• Antifungal In Vitro Activity of Pilosulin- and Ponericin-Like Peptides from the Giant Ant Dinoponera quadriceps and Synergistic Effects with Antimycotic Drugs

  2020cites this paper
• Epidemiology and burden of invasive fungal infections in the countries of the Arab League.

  2020cites this paper
• EVALUATION OF ANTI-CRYPTOCOCCAL ACTIVITY OF BACITRACIN

  2020cites this paper
• Insight to the antifungal properties of Amaryllidaceae constituents.

  2020cites this paper
• Human Antimicrobial Peptide Hepcidin 25-Induced Apoptosis in Candida albicans

  2020cites this paper
• Antifungal Resistance of Candida Spp. in Bloodstream Infection

  2020cites this paper
• New Generation of Antibacterial Products Based on Colloidal Silver

  2020cites this paper
• In-vitro and in-vivo anticandidal activity of Trachyspermum ammi (L.) sprague seeds ethanolic extract and thymol-containing hexanes fraction

  2020cites this paper